Youthful insured not triggering cost spike

Share this article:
Youthful insured not triggering cost spike
Kao-Ping Chua and Benjamin Sommers, authors of the JAMA study

While the US is still months away from clocking a full year of insurance coverage under healthcare reform, the impact that coverage is having on the health expenditures of young people is already beginning to surface.

In short: the clause in the Affordable Care Act that allowed children to be covered by a parent's insurance plan until they turned 26 has not been linked to a statistically significant increase in use of health-related services, but has been associated with a decrease in out-of-pocket healthcare costs among 19-to-25-year-olds and improved self-reported health status, according to a research letter published in the Journal of the American Medical Association on Tuesday.

Although the extended coverage became mandatory last year, employers started extending coverage much earlier, and researchers tracked data from the "post-implementation" year of 2011 through 2012.

Researchers acknowledge that the study is a very brief snapshot, since the sample covers just one year of data, but they found that the ACA's dependent coverage extension indicates greater protection against medical costs compared to adults not affected by the law.

While a 2010 report by the Society for Human Resource Management indicated employers were not thrilled by the requirement they would have to extend coverage by 2014, a 2013 assessment by Health Affairs indicated that employers began extending coverage to the under-26 crowd before they had to. HA also noted that this was one provision of the Affordable Care Act that around 70% of the public had down pat, just six months after healthcare reform passed.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...